MedTrace Logo

Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery

NCT02274870 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2018-06-14

Study results available
· View outcomes & findings →

Summary

Continuous femoral nerve blocks (CFNB) provide effective pain control to patients undergoing total knee replacement (TKR). However the resulting motor blockade can lead to decreased quadriceps muscle strength and delayed functional recovery.The purpose of this study is to compare the effect of Liposome Bupivacaine infiltration into the knee to CFNB on pain control and functional recovery

Conditions

  • Post-operative Pain

Interventions

DRUG

Liposome Bupivacaine

Administered via local tissue infiltration around the knee joint

DRUG

Bupivacaine HCl

Administered via CFNB

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Joseph Marino, MD · Northwell Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-12-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02274870 on ClinicalTrials.gov